Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 24, 2021
- Accepted January 10, 2022
- Published online January 14, 2022.
Copyright & Usage
Copyright © 2022, Parenteral Drug Association
Author Information
- Melisa J. Masuda-Herrera1,15 (melisa.masuda-herrera{at}gilead.com),
- Joel P. Bercu1 (joel.bercu{at}gilead.com),
- Thomas H. Broschard2 (thomas.broschard{at}merckgroup.com),
- Anders Burild3 (qabu{at}novonordisk.com),
- Catrin Hasselgren4 (hasselgren.catrin{at}gene.com),
- Patricia Parris5 (patricia.parris{at}pfizer.com),
- Lucie C. Ford6 (lucie.ford{at}tamu.edu),
- Jessica Graham4 (graham.jessica{at}gene.com),
- Brad Stanard7 (bstanard{at}ultragenyx.com),
- Michele Comerford8 (michele.comerford{at}pfizer.com),
- Daniel Lettiere8 (daniel.j.lettiere{at}pfizer.com),
- Steffen Erler9 (steffen.erler{at}wella.com),
- Courtney M. Callis10 (courtney.callis{at}lilly.com),
- Eric Morinello4 (morinello.eric{at}gene.com),
- Wolfgang Muster11 (wolfgang.muster{at}roche.com),
- Elizabeth A. Martin12 (elizabeth.martin{at}astrazeneca.com),
- Troy R. Griffin13 (troy.griffin{at}tevapharm.com),
- Lee Nagao14 (lee.nagao{at}faegredrinker.com) and
- Maureen Cruz14 (maureen.cruz{at}faegredrinker.com)
- 1 Gilead Sciences;
- 2 Merck KGaA;
- 3 Novo Nordisk A/S;
- 4 Genentech, Inc.;
- 5 Pfizer Worldwide Research and Development;
- 6 Texas A&M University;
- 7 Ultragenyx Pharmaceutical Inc.;
- 8 Pfizer Global Research & Development;
- 9 Wella Company;
- 10 Eli Lilly & Company;
- 11 Roche Pharmaceutical Research & Early Development;
- 12 AstraZeneca;
- 13 Teva Branded Pharmaceutical Products R&D;
- 14 Faegre Drinker Biddle & Reath LLP
- ↵* Corresponding author; email: melisa.masuda-herrera{at}gilead.com
Cited By...
In This Issue
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls)
Jump to section
Related Articles
Cited By...
- No citing articles found.
More in this TOC Section
Similar Articles